Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Healthequity (HQY) Cash & Equivalents (2016 - 2026)

Healthequity (HQY) has 13 years of Cash & Equivalents data on record, last reported at $309.3 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 4.01% year-over-year to $309.3 million; the TTM value through Oct 2025 reached $309.3 million, down 4.01%, while the annual FY2025 figure was $295.9 million, 26.74% down from the prior year.
  • Cash & Equivalents reached $309.3 million in Q4 2025 per HQY's latest filing, up from $304.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $753.8 million in Q3 2021 and bottomed at $161.2 million in Q2 2022.
  • Average Cash & Equivalents over 5 years is $342.4 million, with a median of $300.2 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: surged 330.63% in 2021, then tumbled 78.11% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $649.1 million in 2021, then tumbled by 67.62% to $210.2 million in 2022, then skyrocketed by 58.93% to $334.1 million in 2023, then dropped by 3.56% to $322.2 million in 2024, then decreased by 4.01% to $309.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $309.3 million in Q4 2025, $304.5 million in Q3 2025, and $287.9 million in Q2 2025.